Cite
HARVARD Citation
Freeman, M. et al. (n.d.). 1281PAssessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: A retrospective cohort study. Annals of oncology. p. . [Online].